KPV
Overview
Research-use synthetic tripeptide supplied for studies of melanocortin-associated immune signaling and epithelial barrier pathway models.
- Concentration
- 10 mg
- Stock
- In stock
Product details
KPV is a synthetic Lys-Pro-Val tripeptide corresponding to the C-terminal sequence of alpha-MSH and used in immune and epithelial signaling research models. Pattern lists this material for controlled laboratory research.
Research Targets: Melanocortin-associated signaling, NF-kB pathway models, cytokine signaling, epithelial barrier response systems.
Key Feature: Short alpha-MSH-derived tripeptide for inflammatory-signaling research.
Research Focus Areas: Immune signaling, epithelial barrier models, cytokine response pathways, skin and gut pathway studies.
Common Models: Cell-culture inflammation assays, epithelial cell models, organoid systems, rodent inflammatory pathway studies.
Mechanistic Interests: NF-kB modulation, cytokine expression markers, melanocortin pathway interactions, barrier-associated signaling.
Use Boundary: Research use only; not for human or veterinary use; no diagnostic, therapeutic, or consumption use is implied.
Product documentation
Certificate of Analysis
KPV
Review the public certificate available for this product before creating an account or checking out.
Research context
Peptide guide
Open full guide- Guide profile
- Lys-Pro-Val Tripeptide
- Composition
- Synthetic tripeptide (three-amino-acid sequence: Lysine-Proline-Valine) derived from the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH)
- Discovery
- Identified in late 1990s-early 2000s during research on α-MSH anti-inflammatory mechanisms, isolating the C-terminal tripeptide (Lys-Pro-Val) as the core sequence
- Research scope
- Evidence primarily from preclinical models (cell cultures, rodents) showing KPV reduces inflammation via NF-κB/MAPK inhibition and enhances gut barrier function
- Regulatory status
- No FDA approval for any indication; lacks large-scale RCTs. Human outcome data are sparse, and wellness-community reports are uncontrolled
Safety context
- Hypersensitivity to KPV or components
- Unknown interactions due to limited human data
- Variable quality in compounded forms
Research-use notice: KPV lacks approval from major regulatory bodies for human therapeutic use and remains investigational. Controlled human safety and efficacy data are limited, while most support comes from mechanistic and preclinical inflammation research. Potential risks, interactions, and compounded-product variability are not fully characterized, so clinical decisions require qualified medical oversight.
Full guide includes 10 reference entries.
One kit adds 10 vials to WooCommerce checkout.